Biotronik has announced the European launch of a subcutaneous implantable leadless cardiac monitoring system for patients with atrial fibrillation (AF) or unexplained syncope, bradycardia, sudden rate drop, asystole and tachycardia.
The new system, BioMonitor, uses the company’s ClearSense technology featuring a three-vector signal detection that produces precise and reliable arrhythmia monitoring.
The technology records three ECG channels and converts them to a single ECG input signal, which differentiates between a genuine signal and other artifacts such as myopotentials, caused due to body muscle contractions.
Biotronik claims that the system will provide longevity of 6.4 years, besides detecting and monitoring arrhythmia, independent of the device’s implant orientation within the body.
Leipzig University Heart Centre electrophysiology department director Professor Gerhard Hindricks said; "Only long-term continuous monitoring with reliable arrhythmia detection offers the type of vital information necessary for physicians to make the right therapy decisions when managing patients with AF or unexplained syncope."
In addition, the cardiac device incorporates the company’s home monitoring system, which provides daily remote data transfer without patient interaction.
Charite Campus Virchow cardiology department deputy Professor Wilhelm Haverkamp said the effective management of AF and unexplained syncope starts with effective monitoring.
"BioMonitor®, with its ClearSense technology, and BIOTRONIK Home Monitoring® offer the optimal combination of reliability and efficiency," Haverkamp said.
Rostock University Hospital rhythmology and cardiology department director professor Dietmar Bänsch said; "BioMonitor supports physicians in every step of arrhythmia management, from diagnosis via monitoring to individualised therapy offering high quality solutions that benefit both physicians and patients."
Image: Subcutaneous implantable leadless cardiac monitor differentiates between a genuine signal and other artifacts such as myopotentials. Photo: Courtesy of Yahoo Finance.